Recent Updates
Recently added Catalysts
VTRS Neutral Sentiment Score: 60/100

Viatris to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 Viatris Inc. (NASDAQ: VTRS) plans to report its fourth quarter and full year 2022 financial results on Monday, February 27 before the open of the U.S....

Key Takeaway: Viatris Inc. plans to release its fourth quarter and full year 2022 financial results on February 27, 2023, before the U.S. markets open. The company's executive team will participate in a webcast that day at 8:30 a.m. ET to discuss the results. Investors and the public can access the webcast live or through a replay on the Viatris website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Viatris is set to report its financial results, which may indicate company growth.
  • The company offers over 1,400 approved molecules across numerous therapeutic areas.

Full Press Release Details

PITTSBURGH , Feb. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) plans to report its fourth quarter and full year 2022 financial results on Monday, February 27 before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler , President Rajiv Malik , and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. ET on February 27 to discuss the results.
Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 866.342.8591 or 203.518.9713 for international callers (Conference ID: VTRSQ422). A replay of the webcast also will be available on the website.
Viatris Inc. (NASDAQ: VTRS ) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh , Shanghai and Hyderabad, India . Learn more at viatris.com and investor.viatris.com , and connect with us on Twitter at @ViatrisInc , LinkedIn and YouTube .
SOURCE Viatris Inc.

21 %

Frequently Asked Questions

When does Viatris plan to report its financial results?

Viatris is set to report its fourth quarter and full year 2022 financial results on February 27.

Who will host the Viatris financial results webcast?

CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will host the webcast.

How can I access the Viatris financial webcast?

The webcast is available at investor.viatris.com or by calling specified numbers.

What is the main focus of Viatris Inc.?

Viatris aims to empower global health by providing access to medicines and innovative solutions.

How many approved molecules are in Viatris' portfolio?

Viatris' portfolio includes over 1,400 approved molecules across various therapeutic areas.

Last updated: Feb 15, 2023